Back to News
Market Impact: 0.12
INmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To Board
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
ImmuneBio appointed R. Duane Clark II and James Sapirstein to its board of directors, adding commercial and strategic leadership. The appointments are intended to support the late-stage immunology company's advancement of its Eb program, with no financial or clinical-development metrics disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
INMB0.35
More News
- Anthropic's IPO push includes a big bet on life sciences
- The big questions remaining after Anthropic’s blockbuster IPO prospectus
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
From AllMind Research
- AllMind Platform Feature Updates - Fall 2026
- AI Credit Covenant Monitoring: From Clause to Review
- AI-Led Expert Interviews vs. Transcript Libraries
- AI for Investment Thesis Validation: A Claim-Ledger Method
- Capital Intensity as Gravity: The AI Trade Enters Its Industrial Era (Looking at Q3 2025 Earnings in Tech)